Western blot of HEK293 lysate showing specific immunolabeling of the ~160 kDa MerTK phosphorylated at Tyr749/753/754 in the first lane (-). Phosphospecificity is shown in the second lane (+) where the immunolabeling is completely eliminated by blot treatment with lambda phosphatase (λ-Ptase, 1200 units for 60 minutes).

Western blot of HEK293 lysate showing specific immunolabeling of the ~160 kDa MerTK phosphorylated at Tyr749/753/754 in the first lane (-). Phosphospecificity is shown in the second lane (+) where the immunolabeling is completely eliminated by blot treatment with lambda phosphatase (λ-Ptase, 1200 units for 60 minutes).

from PhosphoSolutions

Anti-MerTK Tyr749/753/754 (p186-749)

  • Sale
  • Regular price $380



Product Details


Details

Volume: 100 µL (Standard), 25 µL (Trial Size)

Concentration: Lot Specific

Clonality: Polyclonal

Form: Antigen Affinity Purified from Pooled Serum

Host Species: Rabbit

Species Reactivity: Human, Mouse, Rat

Applications: WB

Immunogen: Synthetic phospho-peptide corresponding to amino acid residues surrounding human MerTK Tyr749/753/754 conjugated to KLH

Protein Name / Synonyms: mer, pmer, mertk, p186-749, pmertk, axl, phospho-mertk, p-mer, RTK, p-mertk, pmerkt

Target Description: Along with Tyro-3 and Axl, Mer is a member of the TAM family of receptor tyrosine kinases (RTKs). The TAM family of RTKs regulates cell proliferation/survival, cell adhesion and migration, and blood clot stabilization processes, along with the regulation of inflammatory cytokine release (Linger et al, 2008). Additionally, the TAM family has been linked to coagulopathy and cancer when altered experimentally or genetically (Linger et al, 2008). Tri-phosphorylation of MerTK at tyr749, tyr753 and tyr754 has been identified as a key target in platelet aggregation for developing a new anti-platelet drug that decreases bleeding complications, which are current side effects of similar drugs on the market today (Zhang et al, 2013). MerTK is also seen as a therapeutic target for treating lymphoblastic leukemias, melanoma, breast, lung, colon, liver, gastric, kidney, ovarian, uterine and brain cancers (Graham et al, 1994). There has recently been increased interest in synthesizing novel ATP-competitive small molecule tyrosine kinase inhibitors to decrease tri-phosphorylation of MerTK at tyr749, tyr753, and tyr754 as a therapeutic target to treat AML (Lee-Sherick et al, 2013).

Gene ID: MERTK

Antibody Registry ID (RRID): AB_2744537

Physical State: Liquid

Conjugate: Unconjugated

Buffer: 100 µl in 10 mM HEPES (pH 7.5), 150 mM NaCl, 100 µg per ml BSA and 50% glycerol.

Validation and Application Notes

Molecular Weight: 160

Storage

-20 C

NOTE

Aves Labs products are intended for use as research laboratory reagents. They are not intended for use as diagnostic or therapeutic reagents in humans.


back to top